Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism

Zhifu Cui1†, Xingtao Zhao2†, Felix Kwame Amevor1†, Xiaxia Du1, Yan Wang1, Diyan Li1, Gang Shu3, Yaofu Tian1 and Xiaoling Zhao1*

1Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu, China, 2State Key Laboratory of Southwestern Chinese Medicine Resources, Ministry of Education, Chengdu University of Traditional Chinese Medicine, Chengdu, China, 3Department of Basic Veterinary Medicine, Sichuan Agricultural University, Chengdu, China

Quercetin, a naturally non-toxic flavonoid within the safe dose range with antioxidant, anti-apoptotic and anti-inflammatory properties, plays an important role in the treatment of aging-related diseases. Sirtuin 1 (SIRT1), a member of NAD⁺-dependent deacetylase enzyme family, is extensively explored as a potential therapeutic target for attenuating aging-induced disorders. SIRT1 possesses beneficial effects against aging-related diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Depression, Osteoporosis, Myocardial ischemia (M/I) and reperfusion (MI/R), Atherosclerosis (AS), and Diabetes. Previous studies have reported that aging increases tissue susceptibility, whereas, SIRT1 regulates cellular senescence and multiple aging-related cellular processes, including SIRT1/Keap1/Nrf2/HO-1 and SIRT1/PI3K/Akt/GSK-3β mediated oxidative stress, SIRT1/NF-κB and SIRT1/NLRP3 regulated inflammatory response, SIRT1/PGC1α/eIF2α/ATF4/CHOP and SIRT1/PKD1/CREB controlled phosphorylation, SIRT1-PINK1-Parkin mediated mitochondrial damage, SIRT1/FoxO mediated autophagy, and SIRT1/FoxG1/CREB/BDNF/Trkβ-catenin mediated neuroprotective effects. In this review, we summarized the role of SIRT1 in the improvement of the attenuation effect of quercetin on aging-related diseases and the relationship between relevant signaling pathways regulated by SIRT1. Moreover, the functional regulation of quercetin in aging-related markers such as oxidative stress, inflammatory response, mitochondrial function, autophagy and apoptosis through SIRT1 was discussed. Finally, the prospects of an extracellular vesicles (EVs) as quercetin loading and delivery, and SIRT1-mediated EVs as signal carriers for treating aging-related diseases, as well as discussed the ferroptosis alleviation effects of quercetin to protect against aging-related disease via activating
SIRT1. Generally, SIRT1 may serve as a promising therapeutic target in the treatment of aging-related diseases via inhibiting oxidative stress, reducing inflammatory responses, and restoring mitochondrial dysfunction.

**KEYWORDS**
quercetin, aging-related diseases, sirtuin 1, oxidative stress, mitochondrial dysfunction, inflammatory response

**Highlights:**

1. Quercetin, a naturally non-toxic flavonoid within the safe dose range with antioxidant, anti-apoptotic, and anti-inflammatory properties, plays an important role in the treatment of aging-related diseases.

2. Quercetin exerts neuroprotective effects against chronic aging-related diseases via targeting SIRT1 to regulate cellular senescence and multiple aging-related cellular processes such as SIRT1/Keap1/Nrf2/HO-1 and PI3K/Akt/GSK-3β mediated oxidative stress, SIRT1/NF-κB mediated inflammatory response, SIRT1/PGC1α/eIF2α/ATF4/CHOP mediated mitochondrial damage, and SIRT1/FoxO mediated autophagy.

3. Studies on the preventive and therapeutic effects and clinical application of natural SIRT1 activator or synthetic SIRT1 activator on aging-related diseases could provide a strong foundation and basis for investigating further potential target drugs to attenuate aging-related diseases.
1 Introduction

Aging in both animals and humans is positively correlated with a decline in the physiological functions, thereby increasing the occurrence of aging-related diseases; such as neurodegenerative diseases (NDS) (1) including Alzheimer’s disease (AD) (2), Parkinson’s disease (PD) (3), Huntington’s disease (HD) (4), and Depression (5); as well as other related diseases such as Osteoporosis (6), Myocardial ischemia (M/I) and reperfusion (MI/R) (7), Atherosclerosis (AS) (8), and Diabetes (9). A study reported that aging-related NDS caused significant morbidity and economic burden of approximately $25 billion annually in the USA (10). Therefore, several researchers engaged in studies to explore the molecular mechanism of various aging related diseases.

Chronological aging cause subtle changes in the neuronal structure and function of specific neuronal circuits, resulting in significant decrease in dopamine receptors in the striatum and reactive microglia and astrocytes, and the overactivation of proinflammatory microglia which triggers chronic inflammation (11). The production and accumulation of free radicals causes oxidative stress which increases the production of proinflammatory cytokines, leading to neuronal cell death and glial cell activation (12, 13). However, Sir2 (SIRT1) regulates the expression of proinflammatory cytokines such as tumor necrosis factor (TNF), interleukin-1 β (IL-1β), and interferon γ (IFN-γ) during microglial activation (14), as well as alleviates degeneration of dopaminergic neurons (15).

Sirtuin (SIRT), a member of the NAD⁺-dependent deacetylase enzyme family, regulates various cellular targets and functions. SIRT1 is the most widely studied Sir2 in mammals and is considered as a potential therapeutic target for aging-associated disorders (16–18). SIRT1 activation was reported to attenuate other age-associated disorders such as NDS (19–21). Several aging-related markers such as neuroinflammation, oxidative stress, activation of glial cell, inhibition of adaptive neuroplasticity, dysregulation of neuronal Ca²⁺ homeostasis, mitochondrial dysfunction, and cellular senescence elevate the risk of aging-related diseases (22). Studies have indicated that SIRT1 silencing intensify the formation of aging-related inclusions containing alpha-synuclein, increase the number of age-dependent degeneration of dopaminergic neurons, which intensify the progression of related diseases (23). Moreover, excessive production of free radicals causes cell damage, leading to oxidative and nitrosative stress, which disrupts the immune function and hence, induces series of aging-related diseases. SIRT1 modulates the production and accumulation of reactive oxygen species (ROS) in vitro and in vivo, thereby attenuating oxidative stress associated with neurodegeneration (15, 24).

ROS accumulation cause mitochondrial dysfunction and cell death due to excessive inflammation (25), this allows the development of aging-related diseases (26). However, SIRT1 promotes mitochondrial function and regulates mitochondrial homeostasis. Studies have indicated that overexpression of SIRT1 can effectively inhibit cell death, promote cell survival, and prolong the lifespan of cells (27). However, available strategies such as chemical drugs to treat diseases are very expensive, less clinically effective, and have obvious toxic effects. Therefore, researchers are currently studying to develop potent, cheap, safe, and more effective natural alternatives or novel targets to attenuate aging-induced diseases.

Quercetin (2-(3,4-dihydroxy phenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one) (Figure 1) is one of the major naturally non-toxic flavonoids which is widely found in fruits (grapes, peaches) and vegetables (onions, garlic). Quercetin is a lipophilic compound that could be absorbed by simple diffusion across the intestinal membrane, however, it is ingested primarily as a glycoside, which is converted to a glycoside ligand in the intestine, and then release by absorption into the intestinal epithelium through the action of β-glycosidase, and both the intestinal and oral bacteria are involved in this enzymatic hydrolysis. Studies have shown that poor oral bioavailability of single doses (28–30). The poor aqueous solubility of quercetin (~1 mg/mL in water, ~5.5 mg/mL in simulated gastric fluid, and ~28.9 mg/mL in simulated intestinal fluid) and its instability in the physiological media have limited its application in pharmacology (31, 32), great efforts have been made in its
drug delivery systems to address the problem of limited application (33, 34).

Quercetin plays many beneficial roles such as antioxidant (35), anti-inflammatory (36), anti-apoptotic (37) and other biological activities (38) in neuroprotection (39). Reports have indicated that quercetin contain anti-aging properties (31, 40–43). However, the mechanisms through which quercetin exert these functions are complex and the signaling pathways are intertwined. Therefore, our aim in this review was to clarify how quercetin targets SIRT1 to prevent aging-related diseases, elucidate the relationships between the relevant signaling pathways, provide the possible targets and the theoretical basis for quercetin to serve as an effective drug for aging-related diseases.

2 Effects of quercetin on neurodegenerative diseases

2.1 Alzheimer’s disease (AD)

Alzheimer’s disease (AD) is a neurodegenerative disorder, characterized by learning and memory dysfunction at an early stage and eventually evolves into a cognitive disorder. Due to the progression of the disease and limited treatment options, AD has become one of the greatest threats to the modern population, accounting for approximately 45 million patients worldwide. Studies have predicted that by the year 2050, approximately 150 million people may suffer from AD (2).

The mechanisms of AD are related to the deposition of β-amyloid (Aβ) peptides and intracellular neurofibillary tangles consisting of hyperphosphorylated tau protein, which are important characteristics of AD and can lead to serial neuronal loss and brain atrophy (44). SIRT1 regulates the expression of Aβ (45) and tau (46), which are associated with AD. A study using a three-transgenic AD (3XTG-AD) mice model, reported that quercetin (100 mg/kg) significantly improved the biomarkers of neurodegeneration and cognitive and emotional deficits (47).

2.1.1 Regulation of oxidative stress

In addition to its direct toxic effects on neurons, Aβ increases the sensitivity of neurons to harmful factors such as free radicals and oxidative stress, which play important role during AD. Quercetin supplementation reduce microglia aggregation around amyloid plaques in AD mice (48) through various excess protein pathways (49). Activation of SIRT1 was reported to counteract oxidative stress induced by Aβ aggregation (50). In addition, Yu et al. reported that quercetin regulates SIRT1/Nrf2/HO-1 pathway thereby exerting neuroprotective effects against AD (51). In HT22 hippocampal neurons, quercetin was reported to show a neuroprotective effect by promoting phosphoinositide 3-kinase (PI3K)/Akt which could downregulate glycogen synthase kinase 3β (GSK-3β) activity (52), thereby reducing oxidative stress-mediated neuronal death.

2.1.2 Regulation of inflammatory response

Aβ promotes the activation of microglia and the release of inflammatory cytokines. Chronic inflammation is associated with age-related Alzheimer’s disease. Studies have shown that quercetin exerts an anti-neuroinflammatory effects on LPS-activated BV-2 microglial cells (53), by attenuating the production of inflammatory mediators, including nitric oxide (NO) and TNF, as well as reduce the level of inducible NO synthase (iNOS) (54). Quercetin reduces ROS production by promoting the activity of SIRT1 and enhancing the anti-inflammatory activity of NF-κB acetylation in the neural and glial cells, thereby reducing neuronal cell death (55).

2.1.3 Regulation of mitochondrial function

Mitochondria are organelles responsible for ATP production, calcium regulation, and regulation of redox homeostasis. Mitochondrial dysfunction is regarded as the main causative factor of the pathogenesis aging-related AD (56), as a result could inflict damage to neurons, microglia, and astrocytes (57). Microglia phagocytose Aβ and the surrounding Aβ plaques promote the synaptic and neuronal loss in the chronic AD process in the mitochondrial dysfunction and hence, increase LAMPI immunoreactivity, thereby preventing the diffusion of soluble amyloid into the surrounding thin-walled brain (58). In addition, quercetin was found to improve the cognitive function in the APPswe/PS1De9 transgenic mice model during chronic AD, by reducing mitochondrial dysfunction via the activation of AMP-activated protein kinase (AMPK) (59). Moreover, SIRT1 regulates mitochondrial biogenesis and function by directly controlling the activity of proliferator-activated receptor gamma coactivator 1alpha (PGC-1α) through phosphorylation and deacetylation (60), whereas quercetin cause a reduction in the phosphorylation of the eukaryotic initiation factor 2 alpha (eIF2α), as well as activate the expression of transcription factor 4 (ATF4) through the GADD34 induction in the brain, leading to memory improvement in aged mice and delayed memory deterioration at the early stage of APP23 AD model mice (61).

2.1.4 Regulation of autophagy function

Autophagy is the main mechanism underlying the onset and progression of AD (62). FoxO proteins, key substrates of SIRT1, are prominent and necessary factors in the formation of memory and cognitive function (63). Studies in a drosophila AD model have shown that quercetin significantly alleviate chronic AD by restoring the expression of cell cycle protein including cell cycle
proteins B located in the FoxO signaling pathway perturbed by Aβ accumulation (64).

In summary, quercetin exerts neuroprotective effects against chronic AD by targeting SIRT1 to regulate cellular senescence and aging-related multiple cellular processes, including SIRT1/Keap1/Nrf2/HO-1 and PI3K/Akt/GSK-3β mediated oxidative stress, SIRT1/NF-κB mediated inflammatory response, SIRT1/PGC1α/eIF2α/ATF4/CHOP mediated mitochondrial damage, and SIRT1/FoxO mediated autophagy (Figure 2 and Table 1).

2.2 Parkinson’s disease (PD)

Parkinson’s disease (PD) is a common progressive neurodegenerative disease after AD, which affects approximately 1-2% of people at the age ≥ 65 (65). PD is characterized by dopaminergic (DAergic) neuronal deficits and glial dysfunction in the substantia nigra (SN), caused by neuroglial dysfunction and neuroinflammation (66). Studies have shown that α-synuclein (α-SYN) regulates pathological events that cascade the response in PD (67), whereas SIRT1 proteins modulates PD (68).

2.2.1 Regulation of oxidative stress

Oxidative stress is a major inducer of PD pathogenesis. This is because ROS activates α-syn aggregation cascade, together with Lewy bodies, promotes neurodegeneration (69). In a 6-hydroxydopamine (6-OHDA) PD rat model, it was observed that quercetin alleviated the unilateral medial forebrain tract (annigra lesion) or the striatum (part lesion) through the antioxidant, anti-inflammatory, and protective neurotransmitter mechanisms (70–72). The efficacy of quercetin was tested in MitoPark transgenic chronic PD mice model, to ameliorate striatal dopamine depletion and 5-HT neuronal cell loss (73). Other studies have shown that different doses of quercetin reduce oxidative damage by regulating SIRT1/HO-1/Nrf2 pathway, thereby increasing neuronal density (74). Furthermore, Nrf2 modulates ARE/PINK1 expression (75), to restore mitochondrial homeostasis in chronic PD (76).

2.2.2 Regulation of inflammatory response

PD activates microglia to promote inflammatory processes by releasing inflammatory cytokines and chemokines (77). Moreover, degeneration of dopaminergic neurons is induced by the synergy of ROS, neuroinflammation, and loss of other trophic factors (78). In the microglial (N9)-neuronal (PC12) coculture systems, quercetin downregulates the expression of proinflammatory cytokines in the N9 microglia, and reduce apoptosis in the post-neuronal cells (79). Studies have reported that quercetin alleviates manganese-induced neuroinflammation by inhibiting apoptosis and oxidative stress through the SIRT1/
iNOS/NF-κB and HO-1/Nrf2 pathways (80, 81). NLRP3 inflammatory vesicle is one of the most characterized inflammatory vesicles, which can be activated by highly diverse stimuli. NLRP3 is activated by procaspase-1, which in turn induces maturation and secretion of inflammatory vesicles, whereas mitochondrial dysfunction leads to NLRP3 activation by modulating the SIRT1/PGC-1α axis (83). Studies have shown that quercetin impedes microglial activation by inhibiting the interaction between the NLRP3 inflammasome and mitochondrial autophagy to reduce neurotoxicity (39). In aged mice, quercetin was reported to attenuate neuroinflammation by modulating the SIRT1/PGC-1α axis (83).

2.2.3 Regulation of mitochondrial function

Excessive ROS production and accumulation cause mitochondrial dysfunction by α-SYN, which subsequently results in neurodegeneration (80, 84, 85). However, quercetin is significantly induced in MN9D dopaminergic neuronal cells, two major cell survival kinases, and the activation of PD protein kinase D1 (PKD1) and Akt (86). The cAMP response element-binding protein (CREB) and a transcriptional activator of brain-derived neurotrophic factor (BDNF), are involved in microglial activation. Interestingly, quercetin (10 μM) was found to upregulate BDNF gene expression in the dopaminergic neuronal cells through stimulating mitochondrial biology in the dopaminergic neuronal cells via regulating SIRT1/PGC-1α transcriptional activity through CREB generation. Moreover, mitochondria act as a key regulator for NLRP3 in astrocytes amplifying the activity of the NLRP3 inflammasome, as well as promotes IL-1β production.

2.2.4 Regulation of autophagy function

α-SYN regulates autophagosome synthesis, leading to defective autophagy. Quercetin acts as an autophagy enhancer in aged PD rat models and modulate the microenvironment leading to neuronal death (87). PTEN is responsible for inducing putative kinase 1 (PINK1) that contributes to the

---

**TABLE 1** Pharmacological functions of quercetin on AD.

| In vitro and in vivo model | Quercetin Dose | Mechanism | Effect factors | References |
|---------------------------|----------------|-----------|----------------|------------|
| JxTg-AD mouse            | 100 mg/kg      | Prevents β-amyloid aggregation | CA1 and tau↓ | (47)       |
| APP/PS1 mice             | 2 mg/g         | Reduce the Aβ and amyloid deposition and astrogliosis | APP, CTβ1, GFAP, Hevin and SPARC↓ | (55)       |
| AD mice                  | 2 mg/g         | Reduce microglial cell aggregation around amyloid plaques | tau protein↓ | (48)       |
| C57BL/6J female mice     | 50 μM          | Reduce autophagy impairment or ER stress | eIF2α and ATP4↑ | (61)       |
| APPswt/PS1E9 transgenic mouse | 20, 40 mg/kg | Activation of AMPK to improve AD | ROA↑ | (59)       |
| Drosophila               | 0.44 g/L       | Decrease extracellular β-amyloidosis, tauopathy, astrogliosis via FoxO signaling pathway | APP, cyclin B, BACE1, PS1/2, nicastrin, APH-1, PEN-2 | (64)       |
| Primary Culture of Hippocampal Neurons | 20 μM | Improves mitochondrial function, reduce oxidative stress and apoptosis induction through the Sirt1/PGC-1α axis | caspase-3↓ | (60)       |
| PC12 cells               | 10, 20, 40, 80 μM | Promote cell proliferation, and antagonize the toxicity of Aβ via sirtuin1/Nrf2/HO-1 | LDH, AchE ↓ | (51)       |
| HT22 cells               | 5, 10 μM       | Enhancement of PKD/Akt | GST, NQO1, Nrf2, ARE, IRE1, P姨, Akt, GSK-3β↑ | (52)       |
| HT22 cells               | 5, 10 μM       | Induce Tau protein activity and blocked the Ca2+−calpain−p25-CDK5 signaling pathway | tau protein and Ca2+−calpain−p25−CDK5↓ | (44)       |
| BV-2 microglia cells     | 35 μM          | Activate BV-2 microglia at G2/M phase, mitigated inflammatory profile | INOS, TNF, NF-κB, TLR, NLR, MHC II, CD11B/CR3, CD68↓ | (53)       |

h, hours; d, days; w, weeks; m, months; SOD, superoxide dismutase; CAT, catalase; GSH-Px, glutathione peroxidase; PI3K, phosphoinositide 3-kinase; GSK-3β, glycogen synthase kinase 3beta; INOS, inducible nitric oxide synthase; TNF, tumor necrosis factor; TLR, toll-like receptors; PGC-1α, proliferator-activated receptor gamma coactivator 1alpha; SPARC, secreted protein acidic and rich in cysteine; ROA, Raman optical activity; MMP, matrix metalloproteinase; AMPK, AMP-activated protein kinase; eIF2α, eukaryotic initiation factor 2 alpha; and P姨, phosphorylated eIF2α.
development of astrocyte and proliferation, as well as was identify as an essential protein for the removal of the damaged mitochondria via autophagy (88). PINK1-parkin-mediated dysfunction of the mitochondrial autophagy in the astrocytes can impair the integrity of the mitochondria (89), which leads neuronal dysfunction and degeneration (90). Reports have shown that quercetin activates SIRT1, promotes autophagic PINK1 activation, and reduces cytochrome c release, as well as enable caspase activation to maintain mitochondrial integrity, thereby preventing apoptosis (91). Quercetin regulates the protein expression of Bcl2/Bax and the release of cytochrome c, and nuclear translocation of apoptosis-inducing factor (AIF) (92). Quercetin also promotes autophagy and modulates the microenvironment which leads to neuronal death (87).

Therefore, quercetin is a potential therapeutic strategy for alleviating PD by targeting SIRT1. Developing therapies have shown that SIRT1/Nrf2/HO-1 mediated oxidative stress, SIRT1/NF-κB/NLRP3 pathway ameliorates inflammation SIRT1-mediated PKD1/CREB phosphorylation and BDNF gene expression, and regulates mitochondrial disorders in the dopaminergic neurons and SIRT1-PINK1-Parkin mediated mitochondrial autophagy in the astrocytes to maintain mitochondrial function (Figure 3 and Table 2).

### 2.3 Effects of quercetin on Huntington’s disease (HD)

Huntington’s disease (HD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra, as well as progressive motor dysfunction, chorea, dystonia, mood disturbances, memory, and weight loss. Symptoms of HD in humans usually appear between the ages 30-50 years and increase in severity with chronological age (93). Current disease palliative therapies for HD focus on reducing the levels of mutant huntingtin (mHTT) in brain cells (94). The overexpression of SIRT1 was reported to increase the survival in R6/2 HD mice and improve neuropathology and reduced mHTT aggregation in R6/2 models (95).

#### 2.3.1 Regulation of mitochondrial function

In 3-nitropropionic acid (3-NP)-induced HD rat models, quercetin maintain mitochondrial function by attenuating oxidative stress and neurobehavioral disorder (96). In addition, dysfunction of mitochondrial metabolism of mHTT play major role in the pathogenesis of HD which is primarily associated with impair respiratory chain function, thereby increasing ROS production and subsequently results in cell death. Furthermore, the ubiquitin-proteasome system (UPS) or autophagy reduce the...
formation of toxic mHTT aggregates (97). A study showed that inducement of mHTT could decrease the proteasomal activity of UPS which could be reverse by the quercetin (20 μM), thereby attenuating mitochondrial membrane potential damage (98).

### 2.3.2 Regulation of inflammatory response

It was established that quercetin could alleviate HD in rat model by regulating inflammatory changes (IL-1β, IL-6, and TNF) associated with growth factors released from astrocytes by the reduction of microglial proliferation, as well as increasing astrocyte numbers (99). In addition, quercetin reduce anxiety and depression in patients with 3-NP-induced chronic HD (100). This indicate that quercetin plays neuroprotective role in HD by targeting SIRT1 to relieve mHTT aggregation in patients, and restore mitochondrial function and reduce inflammation (Figure 4 and Table 3).

---

**TABLE 2** Pharmacological functions of quercetin on PD.

| In *vitro* and *vivo* model | Quercetin Dose | Mechanism | Effect factors | References |
|----------------------------|---------------|-----------|---------------|------------|
| 7-month-old aging mice     | 35, 70 mg/kg 4 w | Regulates the Sirtuin1/NLRP3 pathway | cleaved caspase 1, IL-1β, IL-18, NLRP3, ASC, MDA and ROS↓ sirtuin1, PS95, BDNF, NGF and GFAP† | (83) |
| parkin+/– x parkin+/− mating mice | 5 μM 24 h | Scavenging damaged mitochondria | TBK1-activated OPTN binding of PINK1-phosphorylated Ubiquitin. | (91) |
| 6-OHDA rat lesion models   | 25, 50 mg/kg 6 w | Improves antioxidants and anti-inflammatory potential and restored neurotransmitters | neuroinflammatory (TNF, IL-1β and IL-6) ↓ LPO, GSH, Nitrite and neurotransmitter (dopamine, norepinephrine, serotonin, GABA, glutamate)? | (72) |
| rats to cadmium            | 25 mg/kg 24 h | Modulates mitochondrial integrity and MAP Kinase signaling | ROS, MAPK, p-Jun N, p38 and ERK↓ PKCβ1, CHAT and ACh↓↑ | (84) |
| Rotenone- and Iron Supplement–Induced Parkinson disease in Experimental Rats | 25, 50 mg/kg 24 h | Neuroprotective effect via antioxidant, anti-inflammatory | TNF, IL-1β and IL-6↓ LPO, GSH, mitochondrial complexes I and IV↑ | (80) |
| rotenone rat model of PD   | 2 ml/kg 4 w | Augments autophagy, ameliorated ER stress-induced apoptosis with attenuated oxidative stress | C/EBP homologous protein (CHOP), Beclin-1, and dopamine↑ | (87) |
| Transient transfections of MN9D cells 12-week-old MitoPark mice | 10, 30 μM 24 h | Up-regulates mitochondrial complex-I activity to repair mitochondrial | Complex-1↓ Cu/Zn- and Mn-SOD, catalase, GSH and GSSG↑ | (73) |
| Adult male Wistar rats     | 25 mg/kg 6 w | Decrease oxidative damage resulting in increased neuron density. | AChε, MDA ↓ GPs, L-dopa, vitamin C, SOD and CAT↑ | (74) |
| PD mouse authenticated mouse microglia BV2 cells | 30 μM 1 h | Reduce mtROS accumulation and alleviated NLRP3 inflammamson activation. | ROS, iNOS, IL-1β, IL-6, TNF, NLRP3 and caspase-1↓ Nrf2↑ | (39) |
| mouse dopaminergic MN9D cells | 10 μM 1 h | Activate PKD1-Akt cell survival signaling axis | PKD1, Akt, PGC-1α, CREB and BDNF↑ | (86) |
| rat pheochromocytoma (PC-12) cells | 10, 50,100 μM 24 h | Neuroprotective effects as effective antioxidants | CuZn-SOD, Mn-SOD, CAT, GSH and GSH-Px↑ | (71) |
| Microglial (N9)-Neuronal (PC12) Coculture System | 0.1 μM 3 h | Rescue neuronal PC12 cells from glial-evoked apoptosis | IL-6, IL-1β, TNF or iNOS ↓ | (79) |
| SK-N-MC human neuroblastoma cell line and Sprague-Dawley (SD) male rat brain | 10, 20 μg/mL 16 w | Alleviate oxidative stress through regulation of apoptosis, iNOS/NF-kB and HO-1/Nrf2 pathways | ROS, TNF-, TNF, IL-1β, IL-6, COX2, iNOS, Bax, Cytochrome, Caspase-3 and PARP-1↓ SOD, Bcl-2↑ | (79) |
| Rat PC12 cells             | 0.1 μM 3 h | Preventive neurodegenerative diseases caused by oxidative stress and apoptosis. | LDH, Bax, caspase-3, Cytochrome c and AIF↓ Bcl-2↑ | (92) |
| 6-OHDA rat lesion models   | 10–100 μM 50–200 mg/kg | Reliable neuroprotective effects | ROS↓ 5-HT, 5-HIAA↑ | (70) |

h, hours; d, days; w, weeks; ROS, reactive oxygen species; 5-HT, 5-hydroxytryptamine; SOD, superoxide dismutase; CAT, catalase; GSH-Px, glutathione peroxidase; TNF, tumor necrosis factor; NLRP3, NOD-like receptor protein 3; IL-1β, interleukin-1β; CREB, cAMP response element binding protein; MDA, malondialdehyde; BDNF, brain-derived neurotrophic factor; GFAP, glial fibrillary acidic protein; LDH, lactate dehydrogenase; and AIF, apoptosis-inducing factor. ↓ downregulation; ↑ upregulation.
2.4 Effects of quercetin on depression

Major depressive disorder may be associated with volumetric indications of accelerated brain aging (101). Disorders of depression and anxiety are common mental ailments that impose a significant global health challenge. However, current conventional antidepressants have limited efficacy, significant side effects and expensive. The structural and functional integrity of the hippocampus is critical for cognitive functions, as well as producing antidepressant effects in response to adverse factors (environmental changes, stress) (102, 103). Moreover, reports have indicated that SIRT1 inhibitors reverse sleep deprivation (SD)-induced depressive and anxiety-like behaviors and hippocampal neuroinflammation (104). The role and possible mechanisms of SIRT1 have revealed novel therapeutic strategies for clinical treatment of depression (105, 106). SIRT1 is required for normal neuronal excitability and regulates depression-related behaviors in a sex-specific manner (107). Activation of the estrogen receptor alpha (ERα)/SIRT1/NF-κB pathway was involved in LPS-induced depression in aged female mice (108).

Fork head box transcription factor G1 (FOXG1) play neuroprotective roles by regulating adult hippocampal

### TABLE 3  Pharmacological functions of quercetin on HD.

| In vitro and vivo model | Quercetin Dose | Mechanism | Effect factors | References |
|------------------------|----------------|-----------|----------------|------------|
| 150Q mutated huntingtin-expressing cells | 20 µM 4d | Improves the activity of the ubiquitin proteasomal system and upregulated UPS | UPS, mHTT↓ | (98) |
| 3-Nitropropionic Acid-Induced Rat Model of Huntington’s Disease | 20 mg/kg 4d | Improves the motor coordination, locomotor functions, and anxiety | Cd11B and glial fibrillary acidic↓ | (99) |
| 3-NP-induced male Wistar rats | 50mg/kg 14d | Alleviates anxiety and depression | body weight and locomotion count↑ | (100) |
| 3-NP-induced female Wistar rats | 25 mg/kg 21d | Against mitochondrial oxidative stress, mitochondrial dysfunctions and neurobehavioral deficits | MDA, ATP levels and ATP/ADP↓ | (96) |

d, days; UPS, ubiquitin-proteasome system; mHTT, mutant huntingtin; MDA, malondialdehyde; SOD, superoxide dismutase; CAT, catalase; 3-NP, 3-nitropropionic acid. ↓ downregulation; ↑ upregulation.

Cui et al. 10.3386/ﬁmmu.2022.943321
neurogenesis (AHN). Quercetin promotes AHN via FoxG1/CREB/BDNF signaling pathway to improve chronic unpredictable mild stress (CUMS)-induced depression-like behaviors (109). In addition, it has been shown that microglial inhibitory pathways exert neuroprotective effects, and astrocyte activation, whereas quercetin significantly reduce the frequency of spontaneous excitatory postsynaptic currents (sEPSCs) and spontaneous inhibitory postsynaptic currents (sIPSCs) to antidepressants (110). Astrocytes secrete neurotrophic factors such as GDNF and BDNF, of which BDNF combined with exercise training attenuated 1,2-dimethylhydrazine-induced depression in rats with colorectal cancer by modulating the BDNF/tyrosine receptor kinase A (TrkB)/β-catenin axis in the prefrontal cortex significantly reduced tumorigenesis and improve depression-like behavior (111), as well as attenuates LPS-induced depression-like behavior in rats by modulating the BDNF-related Copine 6 and TREM1/2 imbalance in the hippocampus and PFC (112), whereas reports showed that quercetin exert antidepressant and cardioprotective effects (113).

Quercetin reduce doxorubicin-induced anxiety by enhancing immune function and reducing oxidative stress in the brain (114). Alteration in the metabolism of monoamine oxidase (MAO) is associated with aging (115), which catalyzes monoamine-containing neurotransmitters such as serotonin 5-hydroxytryptamine (5-HT) (116). Quercetin possess antidepressant-like effects through its antioxidant, anti-inflammatory activities, and also reduce excitotoxicity, as well as increase 5-HT levels (117). Quercetin significantly reduced MAOs activity and increase the activity of antioxidant enzymes (Cu-Zn, SOD, CAT, and GSH-Px) in depressed rats (118). Some studies in olfactory bulbectomy (OB), the surgical removal of the olfactory bulbs, cause specific set of behavioral changes in social behavior, cognitive function, and activity; whereas quercetin shows an antidepressant-like and antioxidant effects in bullectomized mice model via the glutamatergic and oxidonitrergic pathways (119), and mediate neuroinflammatory-apoptotic cascade response (120).

Furthermore, quercetin acts as an antidepressant by targeting SIRT1 to reverse depressive and anxiety-like behaviors and hippocampal neuroinflammation. The FoxG1/CREB/BDNF/TrkB-catenin axis clarify the underlying mechanisms (Figure 5 and Table 4).

3 Effects of quercetin on osteoporosis

Osteoporosis is also a major aging-related disease (121). The rate of reduction of osteogenic differentiation and bone formation is the major cause of aging-related osteoporosis (122). Bone can act indirectly on the brainstem, midbrain and hippocampus, thereby affect the synthesis of multiple neurotransmitters, resulting in neurodegenerative diseases (123), suggesting that improving the conditions affecting neurodegenerative process may be a novel target for the treatment of bone injury. Osteoporosis is characterized by a reduction in the bone mass and bone mineral loss, and

![Mechanisms of quercetin on Depression](https://example.com/mechanisms.png)
TABLE 4 Pharmacological function of quercetin on depression.

| In vitro and in vivo model | Quercetin Dose | Mechanism | Effect factors | References |
|---------------------------|----------------|-----------|----------------|------------|
| Male ICR mice             | 15, 35mg/kg    | Promotes adult hippocampal neurogenesis via FoxG1/CREB/BDNF signaling pathway | FoxG1, p-CREB and BDNF† | (109)      |
|                           | 4 w            |           |                |            |
| Rats                      | 10, 50mg/kg    | Reduces oxidative stress, inhibited inflammation, and regulated a variety of neurotransmitter systems. | MAO, IL-1β and TNF-α↓ | (118)      |
|                           | 8 w            |           |                |            |
| mice                      | 2, 0.5g/kg     | Antidepressant and cardioprotective effects via BDNF-AKT/ERK1/2 signaling | BDNF-TrkB-AKT/ERK1/2↓ | (113)      |
|                           | 6 w            |           |                |            |
| mice                      | 2, 0.5 g/kg    | Improves mice behavioral performance post CSDS. Decreases sIPSCs and sIPSCs | sIPSCs and sIPSCs↑ | (110)      |
|                           | 6 w            |           |                |            |
| Mice                      | 25 mg/kg       | Antioxidant, anti-inflammatory activities, reduced excitotoxicity and augmented 5 HT levels. | TNF and IL-6↓ | (117)      |
|                           | 6 w            |           |                |            |
| Depresslon in rats        | 40 mg/kg       | Alleviates LPS-induced depression-like behaviors via regulating the BDN/Compe 6 and TREM1/2 | TNF, IL-6, caspase-3↓ | (112)      |
|                           | 8 w            |           |                |            |
| Male wistar rat           | 60 mg/kg       | Against chemotherapy-related complications | MDA, TNF, ROS/RNS↓ | (114)      |
|                           | 24 h           |           |                |            |
| OBX-induced depression in | 40, 80 mg/kg   | Suppression of oxidative–nitrosative stress-mediated neuroinflammation-apoptotic cascade | MDA† | (120)      |
| Wistar rats               | 14 d           |           |                |            |
| Olfactory bulbectomy (OB)| 25mg/kg        | Antioxidant effects contribute to its anti-depressive potential | LOOH↑ | (119)      |
|                           | 14 d           |           |                |            |

h, hours; d, days; w, weeks; FOXG1, Forkhead box transcription factor G1; CREB, cAMP response element binding protein; TrKβ, tyrosine receptor kinase A; SOD, superoxide dismutase; CAT, catalase; GSH-Px, glutathione peroxidase; TNF, tumor necrosis factor; IL-1β, interleukin-1β; MDA, malondialdehyde; and BDNF, brain-derived neurotrophic factor. † downregulation; ↑ upregulation.

deterioration of bone microarchitecture, with a greater impact on postmenopausal women. In the United States, approximately 53 million people are at risk of bone mineral loss, however, this number will gradually increase resulting in an economic loss of an annual cost of $25.3 billion (124).

Quercetin is a potential drug for the clinical treatment of osteoporosis and has a significant effect on the structure and conformation of bone morphogenetic protein-2 (BMP-2) via upregulation of bone mineralization which promotes differentiation of bone marrow mesenchymal stem cells (BMSCs), as well as osteoblast-specific genes such as osterix (OSX), dwarf-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteocalcin (OCN), and serum c-terminal type I collagen cross-linked telopeptides at the mRNA and protein expression levels (40, 125). Quercetin promotes osteogenic differentiation and inhibits lipogenic differentiation of mouse bone marrow mesenchymal stem cells (mBMSCs), enhancing AMPK protein phosphorylation and upregulating SIRT1 expression to exert antioxidant effects (126). Thereby promoting bone marrow mesenchymal stem cell proliferation and osteogenic differentiation. Rodent oophorectomy is extensively studied for to determine a reduction in bone mass and an increase in bone turnover in cancellous bone, which is similar to osteoporosis in postmenopausal women (127).

The activation of nicotine and muscarinic receptors (nAChR) in an osteoclast inhibits the receptor activator of nuclear factor-kappa B ligand (RANKL)-dependent osteoclast development, suggesting that it is closely related to sympathetic nerve activity (128). Quercetin has been shown to inhibit RANKL-mediated osteoclastogenesis, osteoblast apoptosis, and inflammatory response, nuclear factor kB (NF-kB) and activator protein 1 (AP-1) are transcription factors that regulates osteoclast differentiation, and signaling pathways associated with β-catenin degradation (129). Quercetin is inhibits osteoclast differentiation in vitro (130). The abundance of phosphorylated p38 MAPK and phosphorylated extracellular signal-regulated kinase (ERK) could be reverse after quercetin treatment, and trigger significant restoration of the Wnt/β-catenin pathway by enhancing the expression of Wnt3, β-catenin, Bax and cytochrome c expression and decrease the expression of Bcl-2, Bcl-XL and caspase-3 (131), regulating autophagy and apoptosis to prevent osteoporosis (132).

In summary, quercetin acts as a therapeutic measure for treating aging-related osteoporosis by targeting SIRT1, via antioxidants pathways, thereby inhibits osteoblast apoptosis, autophagy, and inflammatory responses (Figure 6 and Table 5).
### Table 5: Pharmacological functions of quercetin on osteoporosis.

| In vitro and in vivo model | Quercetin Dose | Mechanism | Effect factors | References |
|----------------------------|----------------|------------|----------------|------------|
| Mice were used for isolating the primary BMSCs | 2, 5 μM 24 h | Promotes antioxidant via activation of the AMPK/SIRT1 | CTX↓ ALP and OC↑ | (126) |
| Rat bone cells | 15, 7.5 mg/kg 10 w | Prevents osteoporosis by regulating the total number of bone cells, maybe through regulating autophagy and apoptosis | LC3, beclin1, and caspase 3↓ Bcl2↑ | (132) |
| Human osteoblast cell line (MG-63) | 25-200 ppm 2 d | Activates osteoprotegerin (OPG) and inhibited RANKL expression | OC and RANKL↓ ALP, OPG and collagen↑ | (133) |
| MC3T3-E1 Cells | 10, 25, 50 μM 2 h | Inhibition Apoptosis via the MAPK and Wnt/β-Catenin signaling pathways | OSX, Runx2, ALP and OCN↑ caspase-3, Bax, cytochrome c, phosphorylated MAPKs and Wnt/β-catenin↓ Bcl-2, Bcl-XL↑ | (131) |
| RAW 264.7 cells | 1-10 μM 24 h | Decrease osteoclastic differentiation induced by RANKL | NF-κB, AP-1↓ | (129) |
| Female SD rats | 50 mg/kg 8 w | Promotes BMSC proliferation and osteogenic differentiation against TNF-α-induced impairments | TNF-α, NF-κB and β-catenin↓ Runx2 and Osterix↑ | (134) |
| Female SD rats | 50, 100, 200 mg/kg 60 d | Downregulates MAPK signaling pathways and prevents the ovariectomy-induced deterioration of bone mineral density (BMD) | CTX-1, TRAP↓ Ca, P, ALP, and P1NP↑ | (135) |

h, hours; d, days; w, weeks; Runx2, related transcription factor 2; OSX, Osterix; OCN, osteocalcin; Cx43, connexin 43; RANKL, receptor activator of nuclear factor-kappa B ligand; TNF, tumor necrosis factor; IL-6, interleukin-6; IFN-γ, interferon γ; SOD, superoxide dismutase; CAT, catalase; GSH, glutathione; ALP, alkaline phosphatase; LC3, microtubule-associated protein light chain 3; OPG, osteoprotegerin; CTX-1, C-terminal telopeptide of type I collagen; P1NP, N-terminal propeptide of type I procollagen; TRAP, Tartrate-resistant acid phosphatase; Runx2, related transcription factor 2.

**Figure 6**
Mechanism of quercetin on osteoporosis. Quercetin as a therapeutic strategy for the treatment of aging-related osteoporosis by targeting SIRT1, via antioxidant pathways, thereby inhibits osteoblast apoptosis, autophagy, and inflammatory responses. Runx2, related transcription factor 2; OSX, Osterix; OCN, osteocalcin; Cx43, connexin 43; RANKL, receptor activator of nuclear factor-kappa B ligand; TNF, tumor necrosis factor; IL-6, interleukin-6; IFN-γ, interferon γ; SOD, superoxide dismutase; CAT, catalase; GSH, glutathione; ALP, alkaline phosphatase; LC3, microtubule-associated protein light chain 3; OPG, osteoprotegerin; CTX-1, C-terminal telopeptide of type I collagen; P1NP, N-terminal propeptide of type I procollagen; TRAP, Tartrate-resistant acid phosphatase; Runx2, related transcription factor 2.
4 Effect of quercetin on aging-related cardiovascular disease

4.1 Myocardial ischemia (M/I) and reperfusion (MI/R)

Myocardial ischemia is an aging-related cardiovascular disease and causes sudden death worldwide (136). Myocardial ischemia (M/I) infarction is caused by an inadequate supply of oxygen to the heart, leading to apoptosis (137). However, cardiomyocytes damage is caused by calcium overload, large amounts of free radical production, and infiltration of inflammatory cells cause reperfusion. Mitochondrial dysfunction is considered an important marker of neuronal death during cerebral MI/R (7).

The cardioprotective effect of quercetin is associated with attenuating oxidative stress induced by aging (138). In a mice model, quercetin was reported to attenuate cardiac damage induced by a high-fat diet (HFD) by restoring myocardial microcirculation, reducing infarct size and improving left ventricular function, myofibrillar and mitochondrial structure (139). Quercetin also improve the tricarboxylic acid cycle and respiratory chain-related enzyme activity in rats with myocardial infarction, as well as decrease the expression of biomarkers of myocardial induced oxidative stress in rats with myocardial infarction (140). In addition, quercetin protects AC16 cells from HG-induced oxidative stress by elevating p-SIRT1, endothelial NOS, and decreasing iNOS (141) through the PI3K/Akt/Nrf2 signaling pathway (142).

Pretreatment with quercetin significantly inhibit inflammatory cascade responses through the downregulation of HMGB1-TLR4-NF-κB signaling pathway (143). Quercetin protects against myocardial apoptosis in vivo via phosphorylation of JNK and p38, increasing Bcl-2 expression and directly or indirectly inhibiting the activation of Bax and caspase 3 (144, 145), as well as ameliorates MI/R-induced apoptosis through SIRT1/PGC-1α signaling (146).

Evidence shows that sympathetic excitatory reflexes exacerbate myocardial injury (147). In a neuropathic pain model a central mechanism through the inhibition of mitochondrial permeability transition pore (mPTP) opening (148) or involving the activation of paraventricular thalamic (PVA) neurons (149) induce cardioprotective effects.

Therefore, quercetin could be used as a potential therapeutic drug for reducing MI/R injury via SIRT1/PI3K/Akt/Nrf2 mediated oxidative stress, SIRT1/PGC1α and HMGB1/TLR4/ NF-κB mediated inflammatory response, and SIRT1/p38 MAPK mediated apoptosis pathways (Figure 7 and Table 6).

4.2 Atherosclerosis (AS)

Atherosclerosis promotes mortality and morbidity in aging-related cardiovascular diseased models (8, 153). Endothelial dysfunction is an important process involved in atherosclerosis.
A solute exchange between the blood and nerve tissues have a direct contact and are intact by the blood-nerve barrier (BNB), consisting of the endothelium surrounding peripheral nerve substructures (155, 156). Oxidized low-density lipoprotein (ox-LDL)-induced oxidative damage to endothelial cells cause atherosclerosis. Thus, oxLDL induces the formation of RAW264.7 macrophage-derived foam cells that exacerbate cellular lipid accumulation, and elevate the levels of ROS that lead to oxidation of LDL particles to produce ox-LDL, whereas quercetin inhibits cholesterol accumulation-induced apoptosis of macrophages, thereby reducing atherosclerosis (157, 158). In addition, quercetin enhances cellular antioxidant function through the Nrf2 pathway (154). Further studies have showed that quercetin inhibits ox-LDL induced oxidative damage in AS via activating SIRT1 and modulating the AMPK/NADPH/AKT signaling pathway (159), as well as inhibits inflammatory/oxidative stress responses in AS via AMPK/SIRT1/NF-kB pathway (160), and attenuated AS by increasing the density of SIRT1 (161). Another reports in mice have indicated that quercetin attenuates high fat diet-induced atherosclerosis in apolipoprotein E knockout mice by alleviating systemic oxidative stress and also inhibit aortic P47phox by blocking the activation of NADPH oxidase-P47phox membrane translocation (162).

During aging, chronic atherosclerosis promotes ROS production and accumulation which eventually cause mitochondria damage, due to mtDNA damage. OxLDL molecules are immunogenic and are associated with innate immunity to pattern recognition receptors, including scavenger receptors and TLR, and NF-kB, whereas quercetin significantly inhibit NLRP3 inflammatory vesicle activation in the ox-LDL-containing macrophages, thereby attenuating cell lipolysis and IL-1β secretion (163). Ex vivo studies have reported that quercetin (25 μM) reduce the HUVVEC expression of VCAM-1, where ICAM-1 was significantly inhibited (164).
Quercetin inhibits the formation of atherosclerotic plaque, and the main mechanism of action is related to the PI3K/AKT-related regulation of caspase-3 and NF-κB activation (165). Moreover, quercetin decrease the mRNA expression of TNF-α and TLR4 in atherosclerotic rats, and the mechanism of action is related to the TLR4-mediated MAPK pathway by reducing the levels of expression of pro-inflammatory cytokines (IL-1β, TNF-α, and IL-10) (166). Dysregulation of TLRs has been reported to increase inflammation and metabolic syndrome which cause the development and progression of atherosclerosis (167).

Therefore, quercetin play an important role in the treatment of atherosclerosis by preventing endothelial cell damage via SIRT1/AMPK/Nrf2 mediated oxidative stress, SIRT1/PI3K/Akt/NF-κB and SIRT1/TLRs/MAPK mediated inflammatory response (Figure 8 and Table 7).

5 Effects of quercetin on diabetes

Diabetes is a metabolic disorder that cause death in human populace worldwide (mostly in elderly people) (169). The International Diabetes Federation reported that people suffering from diabetes equally exhibit neuropathy and neuropathic pain (170). The most common manifestation of diabetic neuropathy is distal symmetric polyneuropathy (DSPN), which affects approximately 30% of diabetic patients with the most relevant clinical manifestations, whereas the incidence of DSPN is approximately 2% per year (171). However, the pathogenesis is unclear, and clinical and epidemiological studies have indicated that oxidative stress and inflammatory processes are important pathological mechanisms in diabetic neuropathy, which is associated with distal symmetric sensorimotor polyneuropathy.

ROS is associated with the development of neuropathy in an experimental diabetes. The findings in streptozotocin (STZ)-injected diabetic rats suggest that oxidative stress cause neurotransmission defects (172–174). Quercetin has been shown to have a beneficial effect on nicotinamide/streptozotocin-induced antidiabetic and antioxidant capacity in Wistar diabetic rats (175, 176), reducing dorsal root ganglion (DRG) neurons damage by oxidative stress (177). Overproduction and accumulation of ROS and reactive carbonyl compounds induces endoplasmic reticulum stress (ERs). Quercetin was found to induce lysosomal defects which triggered ERs and ROS generation, thereby contributing to glioma cell death (29, 178). Quercetin can bypass the GLUT4 translocation insulin regulatory system through the AMPK signaling pathway and its downstream target p38 MAPK, thereby contributing to the correction of insulin resistance (179). An increase AMPK, insulin receptor substrate 1 (IRS-1) and AS160 phosphorylation increase GSK3β under insulin-stimulated conditions (180). Quercetin induces insulin secretion by direct activation of L-
TABLE 7 Pharmacological function of quercetin on atherosclerosis.

| In vitro and in vivo model | Quercetin Dose | Mechanism | Effect factors | References |
|---------------------------|----------------|-----------|----------------|------------|
| male ApoE KO mice        | 100 mg/kg     | Inhibits Gal-3-NLRP3 signaling pathway | NLRP3↓ | (168) |
| 85 patients with CAD     | 120 mg/2m     | Reduce the transcriptional activity of NF-kB in stable coronary artery disease | TNF-α, IL-1β, IL-10 and IkBa↓ | (166) |
| male ApoE KO mice        | 25, 50, 100 mg/kg | Ameliorates atherosclerotic lesions formation | ROS, MDA, NOX4↓ | (162) |
| apolipoprotein E-deficient (ApoE-/-) mice and C57BL/6J (C57) mice | 20 mg/kg/d | Attenuates AS by increasing the density of SIRT1 | sflam-1, IL-6, Vcam-1, and ROS ↓ | (161) |
| high fat diet–induced atherosclerosis in the carotid artery of rats | 30 mg/kg/day | Inhibits inflammatory/oxidative stress responses in AS via AMPK/SIRT1/NF-κB pathway | NF-κB, IL-1β, MDA ↓ | (160) |
| endothelial cells | 2.5, 5, 10 μM | Protects against oxLDL-induced endothelial oxidative damage by activating SIRT1 | NOX2, NOX4, ROS, NADPH, and ox-LDL ↓ | (159) |
| LDL receptor knockout (−/−) mice | 100 μg | Alleviates oxidative stress via diverse pathways, including NF-κB and JAK3 | TNF-α, MCP-1, and IL-1β↓, STAT3, SOCS3, PON1 and SIRT1↑ | (158) |
| RAW264.7 Macrophage Foam Cells | 25, 50 μmol/L | Regulates MST1-Mediated Autophagy | P35, P21, and P16↓ | (157) |
| male C57BL/6 mice | 50, 100 mg/7 kg | Suppress inflammation and apoptosis via ROS-regulated PI3K/AKT | ROS, Caspase-3 and NF-κB↓ | (165) |

| Dose | Effects | References |
|------|---------|------------|
| 16 w | Inhibits Gal-3-NLRP3 signaling pathway | (168) |
| 2 w | Reduce the transcriptional activity of NF-kB in stable coronary artery disease | (166) |
| 24 w | Ameliorates atherosclerotic lesions formation | (162) |
| 48 h | Attenuates AS by increasing the density of SIRT1 | (161) |
| 2 w | Inhibits inflammatory/oxidative stress responses in AS via AMPK/SIRT1/NF-κB pathway | (160) |
| 24 h | Protects against oxLDL-induced endothelial oxidative damage by activating SIRT1 | (159) |
| 30 d | Alleviates oxidative stress via diverse pathways, including NF-κB and JAK3 | (158) |
| 24 h | Regulates MST1-Mediated Autophagy | (157) |
| 7 w | Suppress inflammation and apoptosis via ROS-regulated PI3K/AKT | (165) |

h, hours; d, days; w, weeks; m, months; LC3-II/I, microtubule-associated protein light chain 3-II/I; TNF-α, tumor necrosis factor-α; MCP-1, monocyte chemotactic protein-1; STAT3, signal transducer and activator of transcription 3; SOCS1, suppressor of cytokine signaling 1; SRE1, c-Jun N-terminal kinase; AMPK, AMP-activated protein kinase; NADPH, nicotinamide adenine dinucleotide phosphate; NOX, NADPH-oxidase; GSH-Px, glutathione peroxidase; MDA, malondialdehyde; NLRP3, NOD-like receptor protein 3; ox-LDL, oxidized low-density lipoprotein; TLR4, toll-like receptor 4; MPO, myeloperoxidase; COX-2, Cyclooxygenase-2; 5-LOX, 5-lipoxygenase; NOS, nitric oxide synthase; CRP, C-reactive protein; VCAM-1, vascular cell adhesion molecule-1; ICAM-1, intercellular adhesion molecule-1; ↓, downregulation; ↑, upregulation.

Recent studies have demonstrated that ferroptosis, a newly identified form of regulated cell death characterized by iron-dependent dependence on the overproduction of ROS leading to irreparable lipid peroxidation, is involved in β-cell death leading to reduced insulin secretion. The protective effect of quercetin on mice pancreas occurs partly through the inhibition of hypertrophy (190).

In general, the application of quercetin at the appropriate dose could serve as a potential therapeutic agent in treating diabetes, by attenuating oxidative stress and ferroptosis (Figure 9 and Table 8).

6 Discussion

Aging is an irreversible physiological process, and the incidence of neurological diseases increases with age (192). Neurodegenerative diseases have been recognized as a manifestation of chronological aging (193). Therefore, it is important to identify suitable anti-aging drugs and explore their therapeutic mechanisms. Oxidative stress,
neuroinflammation, apoptosis, autophagy, and mitochondrial dysfunction are significant causative factors related to aging-related diseases (194–197). Recently, numerous studies have reported the protective effects of SIRT1 in aging-related diseases, such as protective effect against neurodegeneration, regulation of oxidative stress, inflammatory response, mitochondrial biogenesis, cell death, and autophagy (17, 18, 198–200). Quercetin is an anti-aging flavonoid, because it possesses antioxidant, anti-apoptotic, anti-inflammatory properties, as well as can actively participate in the improvement of mitochondrial dysfunctions, thereby could be used as a novel therapeutic measure in treating aging-related diseases (29, 59, 96, 196, 201, 202). Therefore, recently researchers focus on investigating the medicinal effects of quercetin and its mechanism in attenuating aging-related diseases.

Several studies have shown that quercetin protects against neurodegenerative diseases by enhancing the mechanism of SIRT1 deacetylase (203, 204). However, low bioavailability and solubility of quercetin limits its clinical application (205). In addition, most of the current studies only focused on quercetin glycosides, however, the functions of the gut microbiota helps to breakdown quercetin into serious biological metabolites such as phloroglucinol, 3,4-dihydroxyphenylacetic acid, 4-hydroxyphenylacetic acid, and 3,4-dihydroxybenzaldehyde (206). Therefore, it is important to examine the potential therapeutic effects of these intestinal metabolites obtained from quercetin.

6.1 Quercetin regulates oxidative stress via SIRT1

Oxidative stress, mitochondrial dysfunction, inflammatory, and cell autophagy and apoptosis are pathophysiological factors responsible for initiating aging-related diseases (207). There is a correlation between oxidative stress and aging (208). Thus, with chronological aging, ROS production and accumulation from multiple sources increases, whereas the levels of antioxidant enzymes and repair systems (proteasomal degradation) decline. Reports have shown that quercetin improve the concentration antioxidant enzymes and anti-inflammarory cytokines, as well as improve mitochondrial function by targeting SIRT1 activity via the SIRT1/AMPK/NF-κB, SIRT1/Keap1/Nrf2/HO-1, and SIRT1/PI3K/Akt pathways (159, 203).

In a rat model, it was indicated that quercetin inhibited ER stress to attenuate oxidative stress-induced apoptosis and prevent the progression of osteoarthritis by activating the SIRT1/AMPK pathway in rat chondrocytes (209), and inhibited oxidative stress responses in diabetic high fat diet-induced atherosclerosis in the carotid artery of rats by modulating AMPK/SIRT1/NF-κB pathway (160). Quercetin inhibited oxidative stress to ameliorate diabetic encephalopathy via SIRT1/ER stress pathway in db/db mice (210), furthermore, it inhibited oxidative stress damage to regulate mitophagy and ER stress via SIRT1/TMBIM6 (transmembrane BAX inhibitor-1 motif-containing 6) in cardiovascular diseases (211), as well as attenuated collagen-
induced oxidative stress in mice arthritis by mediating SIRT1 activation (212). Moreover, Quercetin was found to reduce oxLDL-induced oxidative damage by upregulating AMPK and SIRT1 activity (159); and reduce oxidative damage in the liver and kidney tissues, and NF-κB levels by increasing SIRT1 in diabetes model (187).

### 6.2 Quercetin regulates inflammatory response via SIRT1

The attenuation of the inflammatory response is a potential anti-aging strategy. Senescent cell expression is the most pronounced in post-mitotic cells, whereas mitochondria and lysosomes suffer the most significant aging-related alterations in all organelles. Studies have confirmed that SIRT1 activation can inhibit NF-κB, TLRs, and NLRP3 pathways to reduce inflammation. Activation of these SIRT1-dependent signaling pathways by quercetin result in the modulation of the levels and functions of the inflammatory cytokines (213). Quercetin modulates AMPK/SIRT1/NF-κB pathway to inhibit inflammatory responses in diabetic high fat diet-induced atherosclerosis in the carotid artery of rats (160). In addition, quercetin alleviates inflammatory responses by activating SIRT1 and inhibit NF-κB pathway (159), furthermore, it contributes to anti-inflammatory effect by modulating SIRT1 activation via AMPK/SIRT1/Nrf2/TNFα pathway (203), as well as counteracts cholesterol-induced activation of the NF-κB pathway in the pancreas and normalized the expression of pro-inflammatory cytokines by increasing SIRT1 expression (214), and reduce inflammation response in obesity mice through AMPKα1/SIRT1 pathway (215).

### 6.3 Quercetin regulates mitochondrial function via SIRT1

Mitochondrial dysfunction contributes significantly to aging-related diseases (216–218). However, treatment with quercetin could reduce ROS generation and mitigate mitochondrial dysfunction, thereby maintaining the mitochondrial homeostasis and normal function. Quercetin suppressed oxLDL-induced mitochondrial dysfunction and ROS formation by activating SIRT1 and modulating the AMPK/NADPH/AKT pathway (159), and attenuate mitochondrial dysfunction via activating AMPK/SIRT1
pathway in osteoarthritis rats (219). Moreover, quercetin mitigate cerebral ischemia reperfusion injury and reduce ROS generation in the mitochondria via SIRT1/Nrf2/HO-1 pathway (220).

Quercetin, as SIRT1 agonists, promotes mitochondrial biogenesis thereby attenuates mitochondrial diseases (221), prevented cholesterol-induced mitochondrial bioenergetic dysfunction by upregulating the expression of SIRT1 in the Min6 cells (214), and promotes mitochondrial biogenesis in the brain by activating the transcription of SIRT1 (222, 223). Quercetin as SIRT1/PGC-1α activator was reported to improved cardiac function in aged Mdx/Utrn+/- mice by increasing the protein contents and decrease in inflammatory markers NF-κB in the mitochondria (224).

6.4 Quercetin regulates autophagy and apoptosis via SIRT1

During the occurrence of aging-related diseases, cell become vulnerable to the accumulation of abnormal proteins and damage to the phagocytic lysosomal system, which eventually cause cell death (225). Quercetin-induced autophagy contributes to apoptosis via SIRT1/AMPK pathway in lung cancer cells (226), moreover, quercetin inhibits apoptosis and attenuates intervertebral disc degeneration by promoting SIRT1-dependent autophagy (227), as well as improve MI/R-induced cardiomyocyte apoptosis via SIRT1/PGC-1α pathway (146), and regulate autophagy and mitochondrial ROS homeostasis via Nrf2/PGC-1α/SIRT1 pathway in sodium iodate-induced retinal damage (228). A study identify that quercetin could rescue cardiomyocyte hypoxia by regulating SIRT1/TMBIM6-related mitophagy (211), and reduce renal tubular epithelial cell senescence by activating SIRT1/PINK1/Parkin-mediated mitophagy (229). In addition, other studies have showed that quercetin exerts protective effects against cholesterol-induced apoptosis by improving the expression of SIRT1 and inhibits cytochrome c release in Min6 cells (214).

7 Conclusions and future perspectives

The pharmacological efficacy of quercetin has shown that it possesses promising therapeutic potentials. In this review, we highlighted the role of quercetin in targeting SIRT1 with the aim of preventing aging-related diseases via oxidative stress and inflammation alleviation, as well as the restoration of mitochondrial dysfunction. Therefore, SIRT1 may serve as a potential therapeutic target for the treatment of aging-related diseases.

Recent studies on aging-related diseases have indicated that ferroptosis contributes in the pathogenesis of Alzheimer’s disease (230–232), Parkinson’s disease (233, 234), Huntington’s disease (235), Depression (236–238), Osteoarthritis (239), Myocardial ischemia and reperfusion (MI/R) (240–242), Atherosclerosis (243, 244), and Diabetes (245, 246). Notably, quercetin shows iron-chelating activity and effectively decrease iron deposition in the hearts, kidneys and liver of iron-dextran-overloaded mice (247), and protects bone marrow-derived mesenchymal stem cells from erastin-induced ferroptosis through antioxidant pathway (248). Therefore, quercetin was identified as a ferroptosis inhibitor to alleviate acute kidney injury (249). Moreover, activation of SIRT1 inhibits excess iron-induced ferroptosis of foam cells, thereby providing a novel therapeutic target for atherosclerosis (250), and fisetin attenuated doxorubicin-induced cardiomyopathy by inhibiting ferroptosis via the activation of SIRT1/Nrf2 signaling pathway (251). Thus, acting as an intracellular iron chelators, as well as stimulating cellular degradation systems provide novel mechanisms for aging research and may be potential diagnostic biomarkers for aging-related disease in the future (252). The future challenge is to establish models of ferroptosis on disease-specific basis so that the underlying mechanisms of action can be investigated in detail.

Recently, various studies have suggested that extracellular vesicles (EVs) have multiple advantages over currently available drug delivery vehicles, opening new frontiers for modern drug delivery (253–255). Therefore, EVs can be considered for quercetin loading and delivery for treating aging-related disease. In addition, EVs can successfully communicate between cells and organs in the aging microenvironment and during the occurrence of aging-related diseases (256). In particular, neuron-derived EVs can breach the blood-brain barrier (BBB) and become important carriers of signals between cell types in the central nervous system (CNS) (257).

Recent studies have shown that EVs can reduce glutamate expression in the neurons to improve cognitive function and reduce Aβ plaques in AD model mice by activating the SIRT1 pathway (258). The loss of SIRT1 support could accelerated EV production, which carry pathological α-SYN and preferentially target microglia to induce microglial inflammation (259). The release of circulating EVs with oxidative contents alters redox and mitochondrial homeostasis in the brains of rats, suggesting that SIRT1-mediated EVs obtained from different donors may also be promising materials and tools for anti-aging disease therapy. In this comprehensive review, we have found clues from separate studies and found that quercetin could regulate oxidative stress, inflammatory response, mitochondrial dysfunction, autophagy and apoptosis by activating SIRT1 in aging-related disease. However, there are limited in vivo clinical studies on this subject matter, due to limitations such as low bioavailability and solubility of quercetin and disease complexity, therefore, several clinical in vivo studies should be carried out to explore the pharmacological effects and the
pharmacokinetics of metabolites to establish and identify useful clinical metabolites released from quercetin catabolism by the gut microbiota. Moreover, whether EVs could be considered for quercetin loading and delivery for treating aging-related disease, and whether quercetin could alleviate ferroptosis to protect against aging-related disease by activating SIRT1 requires further studies.

Author contributions

Conceptualization, ZC and XZ (2nd author); Literature review, YW, GS, YT, XD, and DL; Writing – original draft, ZC and XZ (2nd author); Writing – review & editing, ZC, FA, and XZ (2nd author). All authors have read and agreed to the published version of the manuscript.

Funding

This study was financially funded by Sichuan Science and Technology Program (2020JDBC0104), the Key Research & Development Plan of the Department of Science and Technology of Tibet Autonomous Region (XZ202101ZY0002N), the Local Projects Guided by the Central Government from Razi County, Tibet Autonomous Region, and the Projects Funded by the Central Government to Guide Local Scientific and Technological Development from Guizhou province (QIANKEZHONGYINDI[2021]4003).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Zhang W, QJ, Liu GH, Belmonte JCI. The ageing epigenome and its rejuvenation. Nat Rev Mol Cell Biol (2020) 21(5):137–50. doi: 10.1038/s41592-019-0204-5
2. Kalaria RN, Baer GE, Ariga M, Friedrich RP, Galasko D, Hall K, et al. Alzheimer’s disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol (2008) 7(9):812–26. doi: 10.1016/j.lncneurol.2007.1069-8
3. Zhang M, Bian Z. The emerging role of circular RNAs in Alzheimer’s disease. Life Sci (2021) 14:105147. doi: 10.1016/j.lfs.2021.105147
4. Šmoková I, Vodňáška P, Vodňášková K, Hanáková H. Mitophagy in huntington’s disease. Neurochem Int (2021) 154:105152. doi: 10.1016/j.neubiorev.2021.105152
5. Terao T. Neglected but not negligible aspects of antidepressants and their availability in bipolar depression. Brain Behav (2021) 11(6):e2308. doi: 10.1002/brb3.2308
6. Kalinkovich A, Livshits G. Biased and allosteric modulation of bone cell-expressing g protein-coupled receptors as a novel approach to osteoporosis therapy. Pharmacol Res (2021) 171:105794. doi: 10.1016/j.phrs.2021.105794
7. Chouschani ET, Pell VB, Gaude AE, Aksentijevic D, Sundler SV, Robb EL, et al. Skaemic accumulation of succinate controls reperfusion injury through mitochondrial ros. Nature (2014) 515:372–5. doi: 10.1038/nature13909
8. Gueguen N, Lenaers G, Reynier P, Weissig V, Edeas M, Gueguen N, Lenaers G, Reynier P, Weissig V, Edeas M. Mitochondrial dysfunction in mitochondrial medicine: current limitations, pitfalls, and tomorrow. Methods Mol Biol (Clifton NJ) (2021) 227:1–29. doi: 10.1007/978-1-076-1626-8_1
9. Cuadros DF, Peur KB, Caude SP. Spatial epidemiology of diabetes: methods and insights. World J Diabetes (2021) 12(7):1042–56. doi: 10.4239/wjd.v12i7.1042
10. Hui Y, Dan X, Babb J, Wei Y, Hasselbalch SG, Croteau DL, et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurosci (2019) 15(10):565–81. doi: 10.1038/s41582-019-0244-7
11. López-Ortín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell (2013) 153(6):1194–217. doi: 10.1016/j.cell.2013.05.039
12. Emmersral TL, Nijkamp G, Veldic M, Rahman S, Andreazza AC, Morava E, et al. Effect of neuropsychiatric medications on mitochondrial function: for better or for worse. Neurosci Biobehav Rev (2021) 127:555–71. doi: 10.1016/j.neubiorev.2021.05.001
13. Ferrucci L, Fabbri E. Inflammaging: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol (2018) 15(9):505–22. doi: 10.1038/nrcardio.2018.064
14. Mulca P, Grunewald A, Pereira SL. Astrocyte-neuron metabolic crosstalk in neurodegeneration: a mitochondrial perspective. Front Endocrinol (2021) 12:668517. doi: 10.3389/fendo.2021.668517
15. Singh V, Ubaid S. Role of silent information regulator 1 (sirt1) in regulating oxidative stress and inflammation. Inflammation (2020) 43(5):1589–98. doi: 10.1007/s10753-020-0212-9
16. Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. CSH Perspekt Biol (2014) 6(4):at018713. doi: 10.1101/cshperspect.a018713
17. Osborne B, Bentley NL, Montgomery MK, Turner N. The role of mitochondrial sirtuins in health and disease. Free Radical Bio Med (2016) 100:164–74. doi: 10.1016/j.freeradbiomed.2016.04.197
18. Shahgaldi S, Khahnin FR. A comprehensive review of sirtuins: with a major focus on redox homeostasis and metabolism. Life Sci (2021) 282:1189803. doi: 10.1016/j.lfs.2021.1189803
19. Fang Y, Wang X, Yang D, Lu Y, Wei G, Yu W, et al. Relieving cellular energy stress in aging, neurodegenerative, and metabolic diseases, sirt1 as a therapeutic and promising node. Front Aging Neurosci (2021) 13:738686. doi: 10.3389/fgene.2021.738686
20. Bai L, Liu R, Wang R, Xin Y, Wu Z, Ba Y, et al. Attenuation of pb-induced afl generation and autophagic dysfunction via activation of sirt1: neuroprotective properties of resveratrol. Ecotox Environ Safe (2021) 221:112511. doi: 10.1016/j.ecss.2021.112511
21. Pratiwi R, Nantasenamat C, Ruankham W, Suwanjang W, Prachayasittikul V, Prachayasittikul S, et al. Mechanisms and neuroprotective activities of stigmastol against oxidative stress-induced neuronal cell death via sirtuin family. Front Nutr (2021) 8:648995. doi: 10.3389/fnut.2021.648995
22. Zia A, Pourbugher-Shahri AM, Fakhrokhdeh S, Samarghanian S. Molecular and cellular pathways contributing to brain aging. Behav Brain Funct (2021) 17(1):22. doi: 10.1186/s12993-021-01017-9
applications. nanoparticles prepared using quercetin and their cytotoxicity and catalytic −

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−

−
Mitochondrial dysfunction and progressive dopaminergic neurodegeneration in Parkinson's disease. Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and programmed cell death in rotenone model of Parkinson's disease. J Neurochem (2017) 141(5):766–82. doi: 10.1002/jnc.14033

El Horany HE, El-Latif RN, ElBath MM, Eman MN. Ameliorative effect of quercetin on neurochemical and behavioral deficits in rotenone rat model of Parkinson’s disease: Modulating autophagy (Quercetin on experimental Parkinson’s disease). J Biochem Mol Toxic (2016) 30(7):360–9. doi: 10.1002/jbt.21821

Choi J, Kim J, Jeong HK, Kim B, Jou I, Park SM, et al. Pink1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced act and increased PI3K activation, and downregulation of egr-1. Glia (2013) 61(5):800–12. doi: 10.1002/glia.22475

Lazauri M, Siter D, Kane LA, Sarrat SA, Wang C, Burman JL, et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature (2015) 524(7565):309–14. doi: 10.1038/nature14893

Thomas KJ, McCoy MK, Blackinton J, Belina A, van der Brug M, Sandrebring A, et al. Dj-1 acts in parallel to the PINK1/Parkin pathway to control mitochondrial function and autophagy. Hum Mol Genet (2011) 20(8):40–50. doi: 10.1093/hmg/ddq340

Wang C, Liu K, Cao J, Wang L, Zhao Q, Li Z, et al. PINK1-mediated mitophagy maintains pluripotency through optineurin. Cell Proli (2019) 54(3):1303. doi: 10.1111/cpr.13034

Bournival J, Quevau P, Martinoti ML. Protective effects of resveratrol and quercetin against mnp-1 induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol (2009) 29(6):1169–80. doi: 10.1007/s10571-008-9411-2

Jiang M, Wang J, Fu J, Du D, Liang H, West T, et al. Neuroprotective role of Sirt1 in mammalian models of Huntington’s disease through activation of multiple Sirt targets. Nat Med (2011) 17(1):153–8. doi: 10.1038/nm.2558

Sander R, Mehrbrot A. Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid. Implications in huntington’s disease. Biochim Biophys Acta (2013) 1832(3):421–30. doi: 10.1016/j.bbadis.2012.11.018

Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in huntington’s disease. Lancet Neurol (2017) 16(10):837–47. doi: 10.1016/S1474-4422(17)30280-6

Chakraborty J, Rajamma U, Jana N, Mohanakumar KP. Quercetin improves the activity of the ubiquitin-proteasomal system in 50q4 mutated huntingtin-expressing cells but exerts detrimental effects on neuronal survivability. J Neurosci (2015) 35(10):1581–91. doi: 10.1172/jn.2014.10153

Chakraborty J, Singh R, Dutta D, Naskar A, Rajamma U, Mohanakumar KP. Quercetin improves behavioral deficiencies, restores astrocyes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington’s disease. CNS Neurosci Ther (2014) 20(10):9–10. doi: 10.1111/cns.12189

Chakraborty J, Singh R, Dutta D, Naskar A, Rajamma U, Mohanakumar KP. Quercetin improves behavioral deficiencies, restores astrocyes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington’s disease. CNS Neurosci Ther (2014) 20(10):9–10. doi: 10.1111/cns.12189

Chakraborty J, Singh R, Dutta D, Naskar A, Rajamma U, Mohanakumar KP. Quercetin improves behavioral deficiencies, restores astrocyes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington’s disease. CNS Neurosci Ther (2014) 20(10):9–10. doi: 10.1111/cns.12189

Molecular mechanisms underlying protective effects of quercetin on mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and mitopark transgenic mouse models of parkinson’s disease. J Neurochem (2017) 141(1):766–82. doi: 10.1111/jnc.14033

Frontiers in Immunology 22
108. Jiang X, Chen Z, Yu X, Chen J, Sun C, Jing C, et al. Lipopolysaccharide-induced apoptosis is associated with estrogen receptor-A/Nrf2/NF-κB signaling pathway in old female mice. *Neurochem Int* (2021) 148:105097. doi: 10.1016/j.neuint.2021.105097

109. Ma ZK, Zhang RY, Rui WJ, Wang ZQ, Feng X, Quercetin alleviates chronic unpredictable mild stress-induced depression-like behaviors by promoting adult hippocampal neurogenesis via FosG1/Ceblb bdnf signaling pathway. *Behav Brain Res* (2021) 406:113245. doi: 10.1016/j.bbr.2021.113245

110. Zhang J, Ling W, Wang J. Dietary quercetin attenuates depressive-like behaviors by inhibiting astrocyte reactivation in response to stress. *Biochem Biophys Res Commun* (2020) 533(4):1338–46. doi: 10.1016/j.bbrc.2020.10.016

111. Sadighparvar S, Darband SG, Yousufi R, Kaviani M, Ghaderi-Pakdel F, Mihanfar A, et al. Combination of quercetin and exercise training attenuates depression in rats with L2-Dimethylhydrazine-induced colorectal cancer: Possible involvement of inflammation and bdnf signaling. *Exp Physiol* (2020) 105(9):1598–609. doi: 10.1113/epjpe086605

112. Fang K, Li HR, Chen XX, Gao XR, Huang LL, Du AQ, et al. Quercetin alleviates LPS-induced depression-like behavior in rats via regulating bdnf-related imbalance of cpe90 and Treml1 in the hippocampus and pit. *Front Pharmacol* (2019) 10:1544. doi: 10.3389/fphar.2019.01544

113. Wang G, Li Y, Lei C, Lei X, Zuo X, Yang Z, et al. Quercetin exerts antidepressant and cardiprotective effects in estrogen receptor-α deficient female mice via bdnf-Atk/Erk1/2 signaling. *J Steroid Biochem* (2021) 206:105795. doi: 10.1016/j.jsbmb.2021.105795

114. Merouz S, Toumi ML, Tahraoui A. Quercetin mitigates adipocyte-induced anxiety- and depression-like behaviors, immune dysfunction, and brain oxidative stress in rats. *Naunyn-Schmiedeberg's Arch Pharmacol* (2014) 387 (10):921–33. doi: 10.1007/s00210-014-0108-y

115. Rahman MS, Uddin MS, Rahman MA, Samsuuzzaman M, Behl T, Hafeez A, et al. Exploring the role of monooxime oxidative activity in aging and Alzheimer's disease. *Curr Pharm Design* (2021) 27(38):4017–29. doi: 10.2174/13816128276662021071713

116. Ramesh M, Muthuraman A. Quantitative structure-activity relationship (Qua) studies for the inhibition of maos. *Comb Chem High Throughput Screen* (2020) 23(9):887–97. doi: 10.1089/comb.2020.07326

117. Khan N, Najmi AK, Aldhur M. A natural phenolic compound quercetin showed the usefulness by targeting inflammatory, oxidative stress markers and augment 5-HT levels in one of the animal models of depression in mice. *Drug Res* (2019) 69(7):392–400. doi: 10.5604/5778.1548-5518

118. Guan T, Cao C, Hou Y, Li Y, Wei X, Li S, et al. Effects of quercetin on the alteration of serum elements in chronic unpredictable mild stress-induced depressed rats. *Biometals* (2021) 34(3):589–602. doi: 10.1007/s12019-021-00298-w

119. Holzmann I, da Silva LM, Corrêa da Silva JA, Steinbach VM, de Souza MM. Antidepressant-like effect of quercetin in bulbectomized mice and involvement of the antioxidant defenses, and the glutamatergic and oxido-nitroergic pathways. *Pharmacol Biochem Behav* (2015) 136:55–63. doi: 10.1016/j.pbb.2015.07.003

120. Riruwa P, Kumar A. Quercetin suppress microglial neuroinflammatory response and induce antidepressant-like effect in olfactory bulbectomized rats. *Neuroscience* (2013) 255:86–94. doi: 10.1016/j.neuroscience.2013.09.044

121. Morris JA, Kemp JP, Youlten SE, Laurent L, Logan JG, Chai RC, et al. An atlas of genetic inflammation and bdnf signalling. *Nat Genet* (2010) 42(10):921–33. doi: 10.1038/ng.710

122. Rinwa P, Kumar A. Quercetin suppress microglial neuroinflammatory response and induce antidepressant-like effect in olfactory bulbectomized rats. *Neuroscience* (2013) 255:86–94. doi: 10.1016/j.neuroscience.2013.09.044

123. Ruangsuriya J, Charumuranese S, Jiranusornkul S, Sirisuda A, Srinithyanyal S, Srinithyanyal J, et al. Depletion of B-ustetetin and enrichment of quercetin and rutin in cisus quadrangularis Linn fraction enhanced osteogenic but reduced osteoclastogenic marker expression. *BMC Complement Med* (2020) 20(1):1. doi: 10.1186/s12906-020-02892-w

124. Pandey MK, Gupta SC, Karelia D, Gilhooley PJ, Shakibaei M, Aggarwal BB. Nicotinic acetylcholine receptors modulate osteoclastogenesis. *Arthritis Res Ther* (2016) 18:63. doi: 10.1186/s13075-016-0961-x

125. Wattel A, Kamel S, Prouillet C, Petit JP, Lorget F, Obedd E, et al. Flavonoid quercetin decreases osteoclastic differentiation induced by rpnk via a mechanism involving nf κappa b and ap-1. *J Cell Biochem* (2004) 92(2):285–95. doi: 10.1002/jcb.200071

126. Wong SK, Chin KY, Ima-Nirwana S. Quercetin as an agent for protecting the bone: A review of the current evidence. *Int J Mol Sci* (2020) 21(17):6448. doi: 10.3390/ijms202116448

127. Konar M, Sahoo H. Tyrosine mediated conformational change in bone morphogenetic protein - 2: Biophysical implications of protein - phytoestrogen interaction. *Int J Biol Macromol* (2015) 150:727–36. doi: 10.1016/j.jbiomac.2015.02.113
Cui et al. 10.3389/fcell.2012.01202

57. Garelnabi M, Mahini H, Wilson T. Quercetin intake with exercise reduces inflammation and improves hepatic function in high fat fed rats. Am J Cardiol Nutr. 2016:164. doi: 10.1038/microbiol.2016.164

61. Li H, Xiao L, He H, Zeng H, Liu J, Jiang C, et al. Quercetin attenuates atherosclerotic inflammation by inhibiting ga3-Nlrp3 signalling pathway. Mol Nutr Food Res (2021) 65(15):e2000746. doi: 10.1002/mnfr.202000746

63. Zhang X, Li L. The significance of 8-oxygen in aging-related diseases. Aging Dis (2021) 11(5):1329-38. doi: 10.14336/ad.2019.10.2101

65. Wild S, Roglic G, Green A, Sceurie R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27(5):1047-53. doi: 10.2337/dac.27.5.1047

69. Kawai S, Yamada T, Matsuura T, Funahashi T, Nishikawa K. Neutrophilic inflammation and atherosclerosis. Clin Immunol (2012) 142(2):193-201. doi: 10.1016/j.clim.2012.01.007

78. Jang E, Kim IY, Kim H, Lee DM, Seo DY, Lee JA, et al. The effects of resveratrol on serum tumor necrosis factor-alpha levels in streptozotocin-induced diabetic rats. Mediators Inflamm. 2013:1. doi: 10.1155/2013/409539

84. Peng J, Li Q, Li K, Zhu L, Lin X, Lin X, et al. Quercetin improves glucose and lipid metabolism of diabetic rats: Involvement of akt signalling and Sirt 1. J Diabetes Res (2017) 2017:3417306. doi: 10.1155/2017/3417306
Quercetin improves cardiomyocyte vulnerability to hypoxia by regulating Sirt1/caloric restriction or pharmacological activation of Sirt1 to delay the onset of diabetic encephalopathy through Sirt1/Er stress pathway in Db/Db mice. Eur J Neurosci (2021) 25:10.1111/ejn.18949.

Chang X, Zhang T, Meng Q, ShiyuanWang, Yan P, Wang X, et al. Quercetin improves cardiomyocyte vulnerability to hypoxia by regulating Sirt1.

Tmbmnt-related mitophagy and endoplasmic reticulum stress. Oxid Med Cell Longev (2021) 2021:959913. doi:10.1155/2021/959913.

Shen P, Lin W, Ba X, Huang Y, Chen Z, Han L, et al. Quercetin-mediated Sirt1 activation attenuates collagen-induced mice arthritis. J Ethnopharmacol (2021) 279:112413. doi:10.1016/j.jep.2021.112413.

Leyton L, Hott M, Acuña F, Carroca J, Nuñez M, Martín C, et al. Nutraceutical activators of Ampk/Sirt1 axis inhibit viral production and protect neurons from neurodegenerative events triggered during hf infection. Viruses (2020) 5:11.372–62. doi:10.3390/viruses20501175.

Carrasco-Pozo C, Tan KN, Reyes-Farias M, de la Jara N, Ngo ST, Garcia-Diaz DF, et al. The deleterious effect of cholesterol and protection by quercetin on mitochondrial biogenesis of pancreatic B-cells, glycolytic control and inflammation: In vitro and in vivo studies. Redox Biol (2016) 9:229–43. doi:10.1016/j.redox.2016.08.007.

Dong J, Zhang Z, Zhang L, Bian HX, Xu X, Bao R, et al. Quercetin reduces obesity-associated atm inflammation and infection in mice. A mechanism including Ampk1/Sirt1. J Lipid Res (2014) 55(3):363–74. doi:10.1194/jlr.M038786.

Liu C, Bai J, Dan Q, Yang X, Lin K, Fu Z, et al. Mitochondrial dysfunction contributes to aging-related atrial fibrillation. Oxid Med Cell Longev (2021) 2021:530923. doi:10.1155/2021/530923.

Gan Z, Fu T, Kelly DP, Vega RB. Skeletal muscle mitochondrial remodeling in exercise and diseases. Cell Res (2018) 28(10):969–80. doi:10.1038/s41422-018-0078-7.

Lin Y, Xu Z. Fibroblast senescence in idiopathic pulmonary fibrosis. Front Cell Dev Biol (2020) 8:593283. doi:10.3389/fcell.2020.593283.

Qiu L, Luo Y, Chen X. Quercetin attenuates mitochondrial dysfunction and biogenesis via upregulated Ampk/Sirt1 signaling pathway in oe rats. BioMed Pharmacother (2018) 103:156–91. doi:10.1016/j.biopha.2018.05.003.

Yang R, Shen YJ, Chen M, Zhao YJ, Chen SH, Zhang W, et al. Quercetin attenuates ischemia reperfusion injury by protecting the blood-brain barrier through Sirt1 in mcao rats. J Asian Nat Prod Res (2022) 24(3):278–89. doi:10.1080/10286062.2021.1949582.

Valero T. Mitochondrial biogenesis: Pharmacological approaches. Curr Pharm Des (2014) 20(15):1884–9. doi:10.2174/13816120145662007120949.

Cassano RA, Martínez-López EJ, Hita-Contreras F, Camlett-Moiron D, Martínez-Romero R, Catuelo A, et al. The combination of oral quercetin supplementation and exercise prevents brain mitochondrial biogenesis. Genes (2014) 9:5. doi:10.3390/genes905005.

Liu P, Zou D, Yu L, Chen M, Gao Y, Zhou R, et al. Quercetin ameliorates hypoxic-hypoxia-induced memory impairment through mitochondrial and neuron function adaptation via the pgc-1α pathway. Restor Neurol Neurosci (2015) 33(2):141–57. doi:10.3233/rnn-140466.

Ballmann C, Denney TS, Beyers RJ, Quindo Y, Romero M, Amin R, et al. Lifelong quercetin enrichment and cardioprotection in Mdz/Utrr+/–. mice. Am J Physiol Heart Circ Physiol (2017) 312(1):H128–40. doi:10.1152/ajpheart.00552.2016.

Tower J. Programmed cell death in aging. Aging Cell (2015) 23(3):483–90. doi:10.1111/acel.12348.

Heitz CL, Haas AM, Nobile A, Steindel R, Lawrenz K, et al. Tsukahara Y. Quercetin attenuates the protective effects of resveratrol against oxidative stress in the hippocampus. Redox Biol (2020) 37:101436. doi:10.1016/j.redox.2020.101436.

Yang D, He X, Wang D, Peng P, Xu X, Gao B, et al. Quercetin suppresses apoptosis and attenuates intervertebral disc degeneration via the Sirt1-autophagy pathway. Front Cell Dev Biol (2020) 8:613006. doi:10.3389/fcell.2020.613006.

Hsu MY, Huo A, Lin YT, Chen C, Lee CM, Liao WC, et al. Quercetin alleviates the accumulation of superoxide in sodium iodate-induced retinal autophagy by regulating mitochondrial reactive oxygen species homeostasis through enhanced deacetyl-Sod2 via the Nr2f2-Pgc-1α-Sirt1 pathway. Antioxidants (Basel Switzerland) (2021) 10(7):1125. doi:10.3390/antiox10071125.

Liu T, Yang Q, Zhang X, Qin R, Shan W, Zhang H, et al. Quercetin alleviates kidney fibrosis by reducing renal tubular epithelial cell senescence through the Sirt1/Pimk1/mitophagy axis. Life Sci (2020) 257:118116. doi:10.1016/j.lfs.2020.118116.

Aytton S, Wang Y, Douf I, Schneider JA, Brockman J, Morris MC, et al. Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. Mol Psychiatry (2020) 25(11):2932–41. doi:10.1038/s41326-019-0357-7.

Lance DJR, Metselaar L, Greenough M, Bush AI, Aytton SJ. Ferroptosis and Nr2f3: An emerging battlefield in the neurodegeneration of alzheimer’s disease. Essays Biochem (2021) 66(7):925–40. doi:10.1042/ebc20210017.

Chen K, Jiang X, Wu M, Cao X, Bao W, Zhu LQ. Ferroptosis, a potential therapeutic target in alzheimer’s disease. Front Cell Dev Biol (2021) 9:704298. doi:10.3389/fcell.2021.704298.
233. Wang ZL, Yuan L, Li W, Li JY. Ferroptosis in Parkinson’s disease: Gli-neuron crosstalk. Trends Mol Med (2022) 28(4):258–69. doi: 10.1016/j.trends.2022.02.003

234. Zuo Y, Xie J, Li X, Li Y, Thrupathi A, Zhang J, et al. Ferroptosis- mediated ferroptosis involved in parathyroid hormone (PTH) receptor signaling of pancreatic islets: Implication for pancreatic islet dysfunction. J Cell Mol Med (2021) 25(12):8069–81. doi: 10.1111/jcmm.16251

235. Reichert CO, de Freitas FA, Sampaio-Silva J, Rokita-Rosa L, Barros PL, Levy D, et al. Ferroptosis mechanisms involved in neurodegenerative diseases. Int J Mol Sci (2020) 21(22):7865. doi: 10.3390/ijms21227865

236. Portugal-Cunha C, Castanho TC, Amorim L, Moreira PS, Mariz J, Marques F, et al. Iron status is associated with mood, cognition, and functional ability in older adults: A cross-sectional study. Nutrients (2020) 12(11):3594. doi: 10.3390/nu12113594

237. Cao H, Zhuang C, Huang Y, Zhu L, Zhao J, Yang Y, et al. Iron and hippocampal proteome analysis reveals activation of necroptosis and ferroptosis in a mouse model of chronic unpredictable mild stress-induced depression. Behav Brain Res (2021) 407:13261. doi: 10.1016/j.bbr.2021.13261

238. Ji X, Yang X, Yan Z, Chen J, Xu M, Jiang Y, et al. Traditional Chinese formula Xiaoyaosan alleviates depressive-like behavior in mice using regulatory molecules in the brain. Front Cell Dev Biol (2021) 9:799499. doi: 10.3389/fcell.2021.799499

239. Yang J, Hu S, Bian Y, Yao J, Wang D, Liu X, et al. Targeting cell death: Pyroptosis, ferroptosis, apoptosis and necroptosis in osteoarthritis. Front Cell Dev Biol (2021) 9:688605. doi: 10.3389/fcell.2021.688605

240. Yan HF, Tuo QZ, Yin QZ, Lei P. The pathological role of ferroptosis in ischemia/reperfusion-related injury. Zool Res (2020) 41(3):220–30. doi: 10.24272/j.issn.2095-8137.2020.042

241. Chen Y, Fan H, Wang S, Tang G, Zhai C, Shen L. Ferroptosis: A novel therapeutic target for ischemia-reperfusion injury. Front Cell Dev Biol (2021) 9:789948. doi: 10.3389/fcell.2021.789948

242. Li JY, Liu SQ, Yao RQ, Tian YP, Yao YM. A novel insight into the fate of neurons in the blood-brain barrier. Brain Behav (2020) 10(12):e12154. doi: 10.1002/brb3.12154

243. Vinchi F, Porto G, Simmelbauer A, Altamura S, Passos ST, Garbowski M, et al. Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction. Eur Heart J (2020) 41(28):2681–95. doi: 10.1093/eurheartj/ehaa112

244. Lin L, Zhang MX, Zhang L, Zhang D, Li C, Li YL. Autophagy, pyroptosis, and ferroptosis: New regulatory mechanisms for atherothrombosis. Front Cell Dev Biol (2021) 9:809955. doi: 10.3389/fcell.2021.809955

245. Sha W, Hu F, Xi Y, Chu Y, Bu S. Mechanism of ferroptosis and its role in type 2 diabetes mellitus. J Diabetes Res (2021) 2021:999612. doi: 10.1155/2021/999612

246. Wang X, Chen X, Zhou W, Men H, Bao T, Sun Y, et al. Ferroptosis is essential for diabetic cardiomyopathy and is prevented by sulforaphane via Ampk/Erastin pathway. Acta Pharm Sin B (2022) 12(2):708–22. doi: 10.1016/j.apsb.2021.10.005

247. Zhang Y, Gao Z, Liu J, Xu Z. Protective effects of baicalin and quercetin on an iron-overloaded mouse: Comparison of liver, kidney and heart tissues. Nat Prod Res (2011) 25(12):1150–60. doi: 10.1080/14786419.2010.495070

248. Li X, Zeng J, Liu Y, Liang M, Liu Q, Li Z, et al. Inhibitory effect and mechanism of action of quercetin and quercetin diol on iron-induced ferroptosis in bone marrow-derived mesenchymal stem cells. Antioxidants (Basel Switzerland) (2020) 9(3):205. doi: 10.3390/antiox9030205

249. Wang Y, Quan F, Cao Q, Lin Y, Yue C, Bi R, et al. Quercetin alleviates acute kidney injury by inhibiting ferroptosis. J Adv Res (2021) 28:231–43. doi: 10.1016/j.jare.2020.07.007

250. Su G, Yang W, Wang S, Geng C, Guan X. Sirt1-autophagy axis inhibits excess iron-induced ferroptosis of foam cells and subsequently increases il-1b and il-18. Biochim Biophys Acta (2021) 1561:33–9. doi: 10.1016/j.bjba.2021.05.011

251. Li D, Liu X, Pi W, Zhang Y, Yu L, Xu C, et al. Fisetin attenuates doxorubicin-induced cardiomyopathy in vivo and in vitro by inhibiting ferroptosis through Sirt1/Nrf2 signaling pathway activation. Front Pharmacol (2021) 12:808480. doi: 10.3389/fphar.2021.808480

252. Terman A, Brunk UT. Oxidative stress, accumulation of biological ‘Garbage’, and aging. Antioxid Redox Sign (2006) 8(1-2):197–204. doi: 10.1089/ars.2006.8.197

253. Vader P, Mol EA, Pasterkamp G, Schifflers RM. Extracellular vesicles for drug delivery. Adv Drug Deliv Rev (2016) 106(Pt A):148–56. doi: 10.1016/j.addr.2016.02.006

254. Elsharkawy OM, Nordin JZ, Hagey DW, de Jong OG, Schifflers RM, Andaloussi SE, et al. Extracellular vesicles as drug delivery systems: Why and how? Adv Drug Deliv Rev (2020) 159:332–43. doi: 10.1016/j.addr.2020.04.004

255. Herrmann IK, Wood MIA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol (2021) 16(7):748–59. doi: 10.1038/s41565-021-00931-2

256. Yin Y, Chen H, Wang Y, Zhang L, Wang X. Roles of extracellular vesicles in the aging microenvironment and age-related diseases. J Extracell Vesicles (2021) 10:2165. doi: 10.1089/jev.2021.2165

257. Morad G, Carman CV, Hagedorn EI, Perlin JR, Zon LL, Mustafaoğlu N, et al. Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS nano (2019) 13(12):13853–65. doi: 10.1021/acsnano.9b04397

258. Dou Y, Xie J, Tan Y, Zhang M, Zhao Y, Liu X. Neurotransmitter-stimulated neuron-derived sevs have opposite effects on amyloid β-induced neuronal damage. J Nanobiotechnol (2021) 19(1):324. doi: 10.1186/s12951-021-01070-5

259. Xia Y, Zhang G, Kou L, Yin S, Han C, Hu J, et al. Reactive microglias enhance the transmission of exosomal A-synuclein via toll-like receptor 2. Brain Res (2021) 1447(7):2024–37. doi: 10.1016/j.brainres.2021.10.005